Differential roles for DUSP family members in epithelial-to-mesenchymal transition and cancer stem cell regulation in breast cancer

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Boulding, Tara ^a   Wu, Fan ^a   McCuaig, Robert ^a   Dunn, Jennifer ^a   Sutton, Christopher R ^a   Hardy, Kristine ^a   Tu, Wenjuan ^a   Bullman, Amanda ^b,c   Yip, Desmond ^b,c   Dahlstrom, Jane E ^b,c   Rao, Sudha ^a  

^a UNIVERSITY OF CANBERRA   (Australia)

^b CANBERRA HOSPITAL   (Australia)

^c The Australian National University   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; CD24 ANTIGEN; DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PHOSPHATASE 6; E1A ASSOCIATED P300 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; HISTONE H3; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PROTEIN DUSP4; PROTEIN H3K27AC; PROTEIN KINASE C DELTA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CHROMATIN; EP300 PROTEIN, HUMAN; HISTONE; LYSINE; PROTEIN KINASE C; TUMOR MARKER;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER STEM CELL; CHROMATIN STRUCTURE; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE CONTROL; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR DYNAMICS; PLEIOTROPY; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; BREAST TUMOR; CHEMISTRY; CHROMATIN; DEFICIENCY; EPIGENETICS; GENE LOCUS; GENE SILENCING; GENETICS; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROTEIN TRANSPORT;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHROMATIN; DUAL-SPECIFICITY PHOSPHATASES; E1A-ASSOCIATED P300 PROTEIN; EPIGENOMICS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE KNOCKDOWN TECHNIQUES; GENETIC LOCI; HISTONES; HUMANS; LYSINE; MCF-7 CELLS; NEOPLASTIC STEM CELLS; PHOSPHORYLATION; PROTEIN KINASE C; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT;

EID: 84959247267     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0148065     Document Type: Article

References (61)

1. Bray F, Ren JS, Masuyer E, Ferlay J (2013) Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 132: 1133-1145. doi:10.1002/ijc.27711 PMID: 22752881.
2. Nwabo Kamdje AH, Seke Etet PF, Vecchio L, Tagne RS, Amvene JM, Muller JM, et al. (2014) New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers. World J Clin Cases 2: 769-786. doi:10.12998/wjcc.v2.i12.769 PMID: 25516852.
3. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428. doi:10.1172/JCI39104 PMID: 19487818.
4. De Craene B, Berx G (2013) Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13: 97-110. doi:10.1038/nrc3447 PMID: 23344542.
5. Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nature reviews Molecular cell biology 15: 178-196. doi:10.1038/nrm3758 PMID: 24556840.
6. Savagner P, Yamada KM, Thiery JP (1997) The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition. J Cell Biol 137: 1403-1419. PMID: 9182671.
7. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, et al. (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76-83. PMID: 10655586.
8. Chang JT, Mani SA (2013) Sheep, wolf, or werewolf: cancer stem cells and the epithelial-to-mesenchymal transition. Cancer Lett 341: 16-23. doi:10.1016/j.canlet.2013.03.004 PMID: 23499890.
9. Kreso A, Dick JE (2014) Evolution of the cancer stem cell model. Cell Stem Cell 14: 275-291. doi:10.1016/j.stem.2014.02.006 PMID: 24607403.
10. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715. doi:10.1016/j.cell.2008.03.027 PMID: 1848587711.
11. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988. PMID: 12629218.
12. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339: 580-584. doi:10.1126/science.1228522PMID: 23372014.
13. Al-Ejeh F, Smart CE, Morrison BJ, Chenevix-Trench G, Lopez JA, Lakhani SR, et al. (2011) Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis 32: 650-658. doi:10.1093/carcin/bgr028 PMID: 21310941.
14. Loda M, Capodieci P, Mishra R, Yao H, Corless C, Grigioni W, et al. (1996) Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J Pathol 149: 1553-1564. PMID: 8909245.
15. Rojo F, Gonzalez-Navarrete I, Bragado R, Dalmases A, Menendez S, Cortes-Sempere M, et al. (2009) Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin. Clin Cancer Res 15: 3530-3539. doi:10.1158/1078-0432.CCR-08-2070 PMID: 19417026.
16. Wang HY, Cheng Z, Malbon CC (2003) Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett 191: 229-237. PMID: 12618338.
17. Candas D, Lu CL, Fan M, Chuang FY, Sweeney C, Borowsky AD, et al. (2014) Mitochondrial MKP1 is a target for therapy-resistant HER2-positive breast cancer cells. Cancer Res 74: 7498-7509. doi:10.1158/0008-5472.CAN-14-0844 PMID: 25377473.
18. Baglia ML, Cai Q, Zheng Y, Wu J, Su Y, Ye F, et al. (2014) Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome. Breast Cancer Res Treat 148: 211- 220. doi:10.1007/s10549-014-3127-z PMID: 25281216.
19. Armes JE, Hammet F, de Silva M, Ciciulla J, Ramus SJ, Soo WK, et al. (2004) Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers. Oncogene 23: 5697-5702. PMID: 15184884.
20. Kim H, Jang SM, Ahn H, Sim J, Yi K, Chung Y, et al. (2015) Clinicopathological significance of dualspecificity protein phosphatase 4 expression in invasive ductal carcinoma of the breast. J Breast Cancer 18: 1-7. doi:10.4048/jbc.2015.18.1.1 PMID: 25834604.
21. Manzano RG, Martinez-Navarro EM, Forteza J, Brugarolas A (2014) Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers. Int J Oncol 45: 2250-2266. doi:10.3892/ijo.2014.2648PMID: 25201346.
22. Lucci MA, Orlandi R, Triulzi T, Tagliabue E, Balsari A, Villa-Moruzzi E (2010) Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors. Cell Oncol 32: 361-372. doi:10.3233/CLO-2010-0520 PMID: 20413845.
23. Small GW, Shi YY, Higgins LS, Orlowski RZ (2007) Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 67: 4459-4466. PMID: 17483361.
24. Koike Folgueira MA, Brentani H, Carraro DM, De Camargo Barros Filho M, Hirata Katayama ML, Santana de Abreu AP, et al. (2009) Gene expression profile of residual breast cancer after doxorubicin and cyclophosphamide neoadjuvant chemotherapy. Oncol Rep 22: 805-813. PMID: 19724859.
25. Liu Y, Du F, Chen W, Yao M, Lv K, Fu P (2013) Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin. Exp Cell Res 319: 3140-3149. doi:10.1016/j.yexcr.2013.08.023 PMID: 24012960.
26. Watson MB, Lind MJ, Smith L, Drew PJ, Cawkwell L (2007) Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model. Acta Oncol 46: 651-658. PMID: 17562441.
27. Cui Y, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, et al. (2006) Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: A mechanism of tamoxifen resistance. Cancer Res 66: 5950-5959. PMID: 16740736.
28. Zafar A, Wu F, Hardy K, Li J, Tu WJ, McCuaig R, et al. (2014) Chromatinized PKC-theta directly regulates inducible genes in epithelial to mesenchymal transition and breast cancer stem cells. Mol Cell Biol.
29. Adler J, Pagakis SN, Parmryd I (2008) Replicate-based noise corrected correlation for accurate measurements of colocalization. J Microsc 230: 121-133. doi:10.1111/j.1365-2818.2008.01967.x PMID: 18387047.
30. Dinic J, Riehl A, Adler J, Parmryd I (2015) The T cell receptor resides in ordered plasma membrane nanodomains that aggregate upon patching of the receptor. Sci Rep 5: 10082. doi:10.1038/srep10082 PMID: 25955440.
31. Sutcliffe EL, Parish IA, He YQ, Juelich T, Tierney ML, Rangasamy D, et al. (2009) Dynamic histone variant exchange accompanies gene induction in T cells. Mol Cell Biol 29: 1972-1986. doi:10.1128/MCB.01590-08 PMID: 19158270.
32. Sutcliffe Elissa L, Bunting Karen L, He Yi Q, Li J, Phetsouphanh C, Seddiki N, et al. (2011) Chromatin- Associated Protein Kinase C-θ Regulates an Inducible Gene Expression Program and MicroRNAs in Human T Lymphocytes. Molecular Cell 41: 704-719. doi:10.1016/j.molcel.2011.02.030 PMID: 21419345.
33. Zafar A, Hardy K, Wu F, Li J, Rao S (2015) The role of protein kinase-C theta in control of epithelial to mesenchymal transition and cancer stem cell formation. Genomics Data 3: 28-32. doi:10.1016/j.gdata.2014.11.002 PMID: 26484144.
34. Jeffrey KL, Camps M, Rommel C, Mackay CR (2007) Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discov 6: 391-403. PMID: 17473844.
35. He H, Davidson AJ, Wu D, Marshall FF, Chung LW, Zhau HE, et al. (2010) Phorbol ester phorbol-12- myristate-13-acetate induces epithelial to mesenchymal transition in human prostate cancer ARCaPE cells. Prostate 70: 1119-1126. doi:10.1002/pros.21146 PMID: 20333698.
36. Niedel JE, Kuhn LJ, Vandenbark GR (1983) Phorbol diester receptor copurifies with protein kinase C. Proc Natl Acad Sci U S A 80: 36-40. PMID: 6296873.
37. Keyse SM (2008) Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 27: 253-261. doi:10.1007/s10555-008-9123-1 PMID: 18330678.
38. Li B, Carey M, Workman JL (2007) The role of chromatin during transcription. Cell 128: 707-719. PMID: 17320508.
39. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. (2007) High-resolution profiling of histone methylations in the human genome. Cell 129: 823-837. PMID: 17512414.
40. Zentner GE, Tesar PJ, Scacheri PC (2011) Epigenetic signatures distinguish multiple classes of enhancers with distinct cellular functions. Genome Res 21: 1273-1283. doi:10.1101/gr.122382.111 PMID: 21632746.
41. Pasini D, Malatesta M, Jung HR, Walfridsson J, Willer A, Olsson L, et al. (2010) Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes. Nucleic Acids Res 38: 4958-4969. doi:10.1093/nar/gkq244PMID: 20385584.
42. Szerlong HJ, Prenni JE, Nyborg JK, Hansen JC (2010) Activator-dependent p300 Acetylation of Chromatin in Vitro: ENHANCEMENT OF TRANSCRIPTION BY DISRUPTION OF REPRESSIVE NUCLEOSOME- NUCLEOSOME INTERACTIONS. The Journal of Biological Chemistry 285: 31954-31964. doi:10.1074/jbc.M110.148718 PMID: 20720004.
43. Huang WC, Chen CC (2005) Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Mol Cell Biol 25: 6592-6602. PMID: 16024795.
44. Yuan LW, Gambee JE (2000) Phosphorylation of p300 at serine 89 by protein kinase C. J Biol Chem 275: 40946-40951. PMID: 11020388.
45. Nunes-Xavier C, Roma-Mateo C, Rios P, Tarrega C, Cejudo-Marin R, Tabernero L, et al. (2011) Dualspecificity MAP kinase phosphatases as targets of cancer treatment. Anticancer Agents Med Chem 11: 109-132. PMID: 21288197.
46. Lazo JS, Nemoto K, Pestell KE, Cooley K, Southwick EC, Mitchell DA, et al. (2002) Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol Pharmacol 61: 720-728. PMID: 11901209.
47. Landry RP, Martinez E, DeLeo JA, Romero-Sandoval EA (2012) Spinal cannabinoid receptor type 2 agonist reduces mechanical allodynia and induces mitogen-activated protein kinase phosphatases in a rat model of neuropathic pain. The journal of pain: official journal of the American Pain Society 13: 836-848.
48. Vogt A, McDonald PR, Tamewitz A, Sikorski RP, Wipf P, Skoko JJ, et al. (2008) A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone- protected cancer cells. Molecular Cancer Therapeutics 7: 330-340. doi:10.1158/1535-7163.MCT-07-2165PMID: 18245669.
49. Castelli M, Camps M, Gillieron C, Leroy D, Arkinstall S, Rommel C, et al. (2004) MAP kinase phosphatase 3 (MKP3) interacts with and is phosphorylated by protein kinase CK2alpha. J Biol Chem 279: 44731-44739. PMID: 15284227.
50. Marchetti S, Gimond C, Chambard J-C, Touboul T, Roux D, Pouysségur J, et al. (2005) Extracellular Signal-Regulated Kinases Phosphorylate Mitogen-Activated Protein Kinase Phosphatase 3/DUSP6 atSerines 159 and 197, Two Sites Critical for Its Proteasomal Degradation. Molecular and Cellular Biology 25: 854-864. PMID: 15632084.
51. Kinney CM, Chandrasekharan UM, Yang L, Shen J, Kinter M, McDermott MS, et al. (2009) Histone H3 as a novel substrate for MAP kinase phosphatase-1. Am J Physiol Cell Physiol 296: C242-C249. doi:10.1152/ajpcell.00492.2008PMID: 19020052.
52. Crowell S, Wancket LM, Shakibi Y, Xu P, Xue J, Samavati L, et al. (2014) Post-translational regulation of mitogen-activated protein kinase phosphatase (MKP)-1 and MKP-2 in macrophages following lipopolysaccharide stimulation: the role of the C termini of the phosphatases in determining their stability. J Biol Chem 289: 28753-28764. doi:10.1074/jbc.M114.591925 PMID: 25204653.
53. Camps M, Nichols A, Arkinstall S (2000) Dual specificity phosphatases: A gene family for control of MAP kinase function. FASEB J 14: 6-16. PMID: 10627275.
54. Dhanasekaran DN, Reddy EP (2008) JNK Signaling in Apoptosis. Oncogene 27: 6245-6251. doi:10.1038/onc.2008.301 PMID: 18931691.
55. Cai B, Chang SH, Becker EBE, Bonni A, Xia Z (2006) p38 MAP Kinase Mediates Apoptosis through Phosphorylation of BimEL at Ser-65. Journal of Biological Chemistry 281: 25215-25222. PMID: 16818494.
56. Werlen G, Jacinto E, Xia Y, Karin M (1998) Calcineurin preferentially synergizes with PKC-theta to activate JNK and IL-2 promoter in T lymphocytes. The EMBO Journal 17: 3101-3111. PMID: 9606192.
57. Avraham A, Jung S, Samuels Y, Seger R, Ben-Neriah Y (1998) Co-stimulation-dependent activation of a JNK-kinase in T lymphocytes. Eur J Immunol 28: 2320-2330. PMID: 9710210.
58. Villalba M, Coudronniere N, Deckert M, Teixeiro E, Mas P, Altman A (2000) A novel functional interaction between Vav and PKCtheta is required for TCR-induced T cell activation. Immunity 12: 151-160. PMID: 10714681.
59. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, et al. (1999) Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813-822. PMID: 9989833.
60. Ward Y, Wang W, Woodhouse E, Linnoila I, Liotta L, Kelly K (2001) Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways. Mol Cell Biol 21: 5958-5969. PMID: 11486034.
61. Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL (2004) Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia 6: 603-610. PMID: 15548370.